Ovarian Cancer News Feed

Ovarian Cancer Stem Cells: Unraveling a Germline Connection
Ovarian Cancer Stem Cells: Unraveling a Germline ConnectionStem cells are considered the holy grail for tissue regeneration and repair, but remain an elusive phenomenon in ovarian biology. Only recently, studies have uncovered the promising potential of “ovarian stem cell differentiation into female gametes” 1 ...read more
Source: Genetic Engineering & Biotechnology News
Published on Thu, 14 Dec 2017 00:00:00 GMT
Ovarian cancer test: GHS-KIYATEC announce effort to find best treatment
Ovarian cancer test: GHS-KIYATEC announce effort to find best treatmentOvarian cancer patients in the Upstate should soon be able to find out which chemotherapy drugs are more likely to work on their tumors because of new diagnostic tests being developed by a local company and used in clinical trials at Greenville Health ...read more
Source: Greenville Online
Published on Wed, 13 Dec 2017 21:00:00 GMT
How to spot ovarian cancer early? Dallas researchers have new hope for tests
How to spot ovarian cancer early? Dallas researchers have new hope for testsWhile modern medicine has made great strides in cancer treatment, ovarian cancer remains a stubborn killer. Researchers at UT Southwestern Medical Center in Dallas are hoping to help improve the odds. Ovarian is the 10th most common cancer, but ranks fifth ...read more
Source: Dallas News
Published on Mon, 11 Dec 2017 03:00:00 GMT
TESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in Germany
TESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in GermanyZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, without the need for BRCA testing and regardless of biomarker status ZEJULA is the only PARP inhibitor to offer once-daily, oral dosing that enables convenient ...read more
Source: Yahoo Finance
Published on Fri, 15 Dec 2017 02:05:00 GMT
Ovarian Cancer: An Improving Outlook
Ovarian Cancer: An Improving OutlookAnya Khomenko, survivor of ovarian cancer, explains how she believed she would soon die following her diagnosis. Justin Chura, MD, highlights how the outlook has improved for patients. Today, we are focusing on recent treatment advances and how patients ...read more
Source: Cure Today
Published on Fri, 15 Dec 2017 09:38:00 GMT
Combination immunotherapy holds promise as improved ovarian cancer treatment
Combination immunotherapy holds promise as improved ovarian cancer treatmentResearchers from the Johns Hopkins Kimmel Cancer Center have demonstrated that mice with ovarian cancer that were treated with combination immunotherapy—receiving drugs to reactivate dormant genes along with other drugs that activate the immune system ...read more
Source: HUB
Published on Thu, 07 Dec 2017 08:46:00 GMT
Texas State cancer-surviving soccer coach raises money for fighting ovarian cancer
Texas State cancer-surviving soccer coach raises money for fighting ovarian cancerThe Texas State women's soccer head coach has presented a $4,531 check to benefit a Texas Oncology Foundation scholarship. The scholarship assists women battling ovarian cancer in Central Texas. Texas State women's soccer head coach Kat Conner herself ...read more
Source: KVUE
Published on Tue, 12 Dec 2017 21:51:00 GMT
Why Clovis' Good News In Ovarian Cancer Prodded These Rivals Down
Why Clovis' Good News In Ovarian Cancer Prodded These Rivals DownClovis Oncology (CLVS) rose Wednesday to the detriment of Tesaro (TSRO) and AstraZeneca (AZN) after the Food and Drug Administration accepted its application for expanded use of its cancer drug, Rubraca. X In afternoon trading on the stock market today ...read more
Source: Investor's Business Daily
Published on Thu, 07 Dec 2017 08:55:00 GMT
Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drug
Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drugThe U.S. Food and Drug Administration has granted a fast-tracked review of using a Clovis Oncology drug to treat a wider range of ovarian cancer patients. The Boulder-based company (Nasdaq: CLVS) seeks approval to use its ovarian cancer drug, rucaparib, as ...read more
Source: The Business Journal
Published on Tue, 05 Dec 2017 13:59:00 GMT